Technology

A novel approach to CRISPR

EXCISION

Approach

Dual gRNAs excise large sections of viral DNA, eliminating viral escape and reproduction. The result is curative.

Large Deletion,

No Probability of Escape

DISCOVERY

Platform

Excision's platform enables in silico design of probes to analyze on- and off-target effects and integrates computational methods to design the most effective guide RNAs.

We are transforming drug discovery and target validation from traditional to digital.

THERAPEUTIC

Pipeline

Pre-Clinical In Vitro Studies

Pre-Clinical In Vivo Studies

IND Filing

EBT-101 HIV AAV9 Cas9 dual gRNA Therapeutic

2020

EBT-103 PML/JCV AAV9 Cas9 triplet gRNA T-antigen Therapeutic

Q4 2022

EBT-104 HSV AAV or non-viral Cas9 quad gRNA Therapeutic

Q1 2023

EBT-107 HBV AAV or non-viral CasX dual gRNA Therapeutic

Q2 2023

EBT-201 COVID-19 Treatment & Prevention: CasY, Cas9, Cas13a

In Development